![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, March 29, 2020 7:03:03 AM
GROWTH OPPORTUNITY FOR LEADING PLAYERS: VERNALIS, LEWIS AND CLARK PHARMACEUTICALS, HEPTARES THERAPEUTICS, ADVINUS THERAPEUTICS
The Adenosine A2 Receptor Antagonist Market is witnessing growth due to the presence of large pool of patients and technological advancements. The increasing compliance for Adenosine A2 Receptor Antagonist industry and massive unexplored market in the emerging economies, such as India and China are creating opportunities for the growth of the global Adenosine A2 Receptor Antagonist market. The advanced research and development facilities by the key players are propelling the demand for improved and cost effective products; further fuelling the growth of the global market.
The intelligence in Adenosine A2 Receptor Antagonist Market report includes investigations based on the current scenarios, historical records, and future predictions. Conclude an accurate data of various aspects. It presents the 360° overview of the competitive landscape of the industries. Thus, helping the companies to understand the threats and challenges in front of the businesses
Acorda bought Biotie and its adenosine A2A receptor antagonist drug tozadenant (SYN115) in a $363 million deal at the beginning of 2016, after seeing positive mid-stage data.
Recent RBSH News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 09:19:43 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:36:33 PM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM